Trial Profile
An Exploratory, Open-label Phase Ib Study of RNActive-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs CV 9202 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors CureVac
- 04 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 12 Apr 2015 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.